GlassScriptPhysician profile
Gregory J Legris
NPI 1336112192
$7,755.08
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $1,004 · 2021: $1,320 · 2022: $3,139 · 2023: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,234.43 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,207.24 | 2019-2023 | Tezspire |
| Glaxosmithkline, LLC. | $864.39 | 2019-2023 | Nucala |
| Regeneron Healthcare Solutions, INC. | $575.55 | 2019-2023 | Dupixent |
| Chiesi USA, INC. | $442.79 | 2019-2022 | |
| Abbvie INC. | $382.78 | 2019-2021 | |
| Genentech USA, INC. | $347.19 | 2019-2023 | Xolair |
| Philips North America LLC | $246.31 | 2020-2022 | |
| Amgen INC. | $237.88 | 2022 | |
| Pharming Healthcare, INC. | $177.92 | 2022-2023 | Joenja, Ruconest |
| Advanced Respiratory, INC | $158.29 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $147.44 | 2020-2023 | |
| Baxter Healthcare | $116.55 | 2022 | |
| Covis Pharma Gmbh | $104.46 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $82.98 | 2020-2022 | |
| Sobi, INC | $65.66 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.19 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $61.20 | 2020-2022 | |
| Electromed, INC. | $37.72 | 2021-2022 | |
| Insmed, INC. | $29.00 | 2019 | |
| Mylan Specialty L.P. | $21.68 | 2022 | |
| Sarepta Therapeutics, INC. | $20.45 | 2021 | |
| Hikma Pharmaceuticals USA | $17.15 | 2022 | |
| Biogen, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Legris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.